Erste Asset Management GmbH Buys New Stake in Guardant Health, Inc. (NASDAQ:GH)

Erste Asset Management GmbH purchased a new position in Guardant Health, Inc. (NASDAQ:GH - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 932,600 shares of the company's stock, valued at approximately $21,389,000. Erste Asset Management GmbH owned approximately 0.75% of Guardant Health as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in GH. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of Guardant Health by 21.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,449 shares of the company's stock valued at $102,000 after acquiring an additional 796 shares in the last quarter. JNBA Financial Advisors purchased a new position in Guardant Health in the 3rd quarter valued at $26,000. Ashton Thomas Securities LLC purchased a new position in Guardant Health in the 3rd quarter valued at $34,000. Quarry LP acquired a new stake in Guardant Health during the 2nd quarter worth $44,000. Finally, Green Alpha Advisors LLC grew its holdings in shares of Guardant Health by 23.6% during the third quarter. Green Alpha Advisors LLC now owns 8,782 shares of the company's stock worth $201,000 after buying an additional 1,674 shares in the last quarter. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. Piper Sandler upped their price target on Guardant Health from $30.00 to $34.00 and gave the company an "overweight" rating in a research report on Tuesday, August 13th. UBS Group raised their target price on Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, August 21st. The Goldman Sachs Group upped their price objective on shares of Guardant Health from $32.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, November 7th. Leerink Partners reduced their target price on shares of Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a research note on Thursday, October 17th. Finally, Craig Hallum increased their price target on shares of Guardant Health from $28.00 to $37.00 and gave the company a "buy" rating in a research note on Thursday, August 8th. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company's stock. According to data from MarketBeat, Guardant Health has a consensus rating of "Moderate Buy" and a consensus target price of $40.60.

Guardant Health Stock Up 1.5 %

Shares of NASDAQ GH traded up $0.51 during midday trading on Friday, hitting $35.61. 815,237 shares of the company's stock were exchanged, compared to its average volume of 2,345,106. The firm's fifty day simple moving average is $25.21 and its 200-day simple moving average is $27.35. The company has a market cap of $4.40 billion, a PE ratio of -8.40 and a beta of 1.11. Guardant Health, Inc. has a twelve month low of $15.81 and a twelve month high of $37.04. The company has a debt-to-equity ratio of 16.70, a current ratio of 6.22 and a quick ratio of 5.85.

Guardant Health (NASDAQ:GH - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.33). The business had revenue of $191.48 million for the quarter, compared to analysts' expectations of $170.49 million. Guardant Health had a negative return on equity of 1,200.44% and a negative net margin of 74.02%. The business's revenue was up 33.9% on a year-over-year basis. During the same quarter last year, the business posted ($0.73) earnings per share. Research analysts predict that Guardant Health, Inc. will post -3.38 EPS for the current fiscal year.

Insider Activity at Guardant Health

In other news, Director Meghan V. Joyce sold 2,896 shares of the firm's stock in a transaction that occurred on Wednesday, November 13th. The stock was sold at an average price of $29.90, for a total value of $86,590.40. Following the completion of the sale, the director now directly owns 7,648 shares of the company's stock, valued at $228,675.20. This trade represents a 27.47 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 5.50% of the stock is currently owned by insiders.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.